Ubiquitin Activation (E1, E2 Enzymes) Antibody Sampler Kit #8645
Inquiry Info. # 8645
Please see our recommended alternatives.
Product Information
Kit Usage Information
Protocols
- 3933: Western Blotting, Immunohistochemistry (Paraffin)
- 4330: Western Blotting, Immunoprecipitation (Magnetic)
- 4890: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 4997: Western Blotting
- 6999: Western Blotting, Immunoprecipitation (Magnetic)
- 7074: Western Blotting
- 8721: Western Blotting, Immunoprecipitation (Magnetic)
Product Description
The Ubiquitin Activation (E1, E2 Enzymes) Antibody Sampler Kit provides an economical means to study ubiquitin activation and conjugation. This kit contains enough primary antibody to perform four western blots per primary.
Specificity / Sensitivity
Ubiquitin Antibody recognizes endogenous levels of ubiquitin, polyubiquitin, and ubiquitinated proteins. This antibody may cross-react with recombinant NEDD8. UBE1a Antibody recognizes endogenous levels of total UBE1a protein. UBC3 Antibody recognizes endogenous levels of total UBC3 and UBC3B proteins. UbcH5C (D60E2) Rabbit mAb recognizes endogenous levels of total UbcH5C protein. UBE2L3 (D5G1) Rabbit mAb recognizes endogenous levels of total UBE2L3 protein. UBE2N (D2A1) Rabbit mAb recognizes endogenous levels of total UBE2N protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the amino terminus of the human ubiquitin protein, the amino terminus of human UBE1 protein, or the sequence of human UBC3 protein. Polyclonal antibodies are purified by protein A and peptide affinity chromotography.
Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp135 of human UbcH5C protein, residues surrounding Leu125 of human UBE2L3 protein, or residues near the carboxy terminus of human UBE2N protein.
Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp135 of human UbcH5C protein, residues surrounding Leu125 of human UBE2L3 protein, or residues near the carboxy terminus of human UBE2N protein.
Background
Ubiquitin is a conserved polypeptide unit that plays an important role in the ubiquitin-proteasome pathway. Ubiquitin can be covalently linked to many cellular proteins for degradation by the 26S proteasome. Three components are involved in the target protein-ubiquitin conjugation process. Ubiquitin is first activated by forming a thioester complex with the ubiquitin-activating enzyme (UBE1 or E1). The activated ubiquitin is subsequently transferred to the ubiqutin-carrier protein (conjugating enzyme) E2, and then from E2 to ubiqutin ligase E3 for final delivery to the epsilon-NH2 of the target protein lysine residue (1-3). The ubiquitin-proteasome pathway has been implicated in a wide range of normal biological processes and in disease-related abnormalities. Several proteins such as IκB, p53, cdc25a, and Bcl-2 have been shown to be targets for the ubiquitin-proteasome process as part of the regulation of cell cycle progression, differentiation, cell stress response, and apoptosis (4-7). UBC3, the mammalian ortholog of yeast cdc34, and UBC3B, a UBC3 family member, are E2 ubiquitin-carrier proteins. UBC3, in concert with SCF-Skp2 (Skp1, Cullin, F-box protein/Skp2) complex, mediates cell cycle progression from G1 to S phase by targeting the CDK inhibitor p27 for proteolysis (8). UBC3B, in concert with SCFb-Trcp (Skp1, Cullin and F-box protein/b-Trcp) complex, mediates degradation of β-catenin (9). UbcH5C is a universally expressed E2 ubiquitin conjugating enzyme and member of the UbcH5 family that also includes UbcH5A and UbcH5B (10). Evidence suggests that UbcH5 plays an important role in regulating a number of signaling pathways by catalyzing the ubiquitination of key target proteins, including p53, PCNA, the IκB kinase proein NEMO, and the apoptosis inhibitor BRUCE (11-14). UBE2L3, also commonly referred to as UBCH7, is a ubiquitin-conjugating enzyme that has been linked to the ubiquitination of numerous substrates via its interaction with protein-ubiquitin E3 ligases, such as NEDD4 (15), E6AP (16), Parkin (17), c-Cbl (18), and Triad1 (19,20). UBE2N/Ubc13 is a ubiquitin-E2-conjugating enzyme that catalyzes K63-linked polyubiquitin chain formation (21,22). UBE2N forms a heterodimer with MMS2 or Uev1A to exert its E2 ligase function. The UBE2N/MMS2 and UBE2N/Uev1A heterodimers catalyze different modes of target protein ubiquitination to mediate various signaling pathways (23-25) including DNA damage and recombination, p53 and check point control, cell cycle (26-30), immunoreceptor signaling (31,32), and endocytosis (33).
- Ciechanover, A. (1998) EMBO J 17, 7151-60.
- Hochstrasser, M. (2000) Nat Cell Biol 2, E153-7.
- Hochstrasser, M. (2000) Science 289, 563-4.
- Bernardi, R. et al. (2000) Oncogene 19, 2447-54.
- Aberle, H. et al. (1997) EMBO J 16, 3797-804.
- Salomoni, P. and Pandolfi, P.P. (2002) Nat Cell Biol 4, E152-3.
- Jesenberger, V. and Jentsch, S. (2002) Nat Rev Mol Cell Biol 3, 112-21.
- Pagano, M. et al. (1995) Science 269, 682-5.
- Semplici, F. et al. (2002) Oncogene 21, 3978-87.
- Jensen, J.P. et al. (1995) J Biol Chem 270, 30408-14.
- Saville, M.K. et al. (2004) J Biol Chem 279, 42169-81.
- Zhang, S. et al. (2008) Cell Cycle 7, 3399-404.
- Tang, E.D. et al. (2003) J Biol Chem 278, 37297-305.
- Qiu, X.B. et al. (2004) EMBO J 23, 800-10.
- Anan, T. et al. (1998) Genes Cells 3, 751-63.
- Huang, L. et al. (1999) Science 286, 1321-6.
- Shimura, H. et al. (2001) Science 293, 263-9.
- Yokouchi, M. et al. (1999) J Biol Chem 274, 31707-12.
- Marteijn, J.A. et al. (2009) Leukemia 23, 1480-9.
- Marteijn, J.A. et al. (2005) Blood 106, 4114-23.
- Herrmann, J. et al. (2007) Circ Res 100, 1276-91.
- Wilkinson, K.D. et al. (2005) EMBO Rep 6, 815-20.
- Hofmann, R.M. and Pickart, C.M. (1999) Cell 96, 645-53.
- Deng, L. et al. (2000) Cell 103, 351-61.
- Andersen, P.L. et al. (2005) J Cell Biol 170, 745-55.
- Zhao, G.Y. et al. (2007) Mol Cell 25, 663-75.
- Kolas, N.K. et al. (2007) Science 318, 1637-40.
- Laine, A. et al. (2006) Mol Cell Biol 26, 8901-13.
- Huen, M.S. et al. (2008) Mol Cell Biol 28, 6104-12.
- Loring, G.L. et al. (2008) Cell Cycle 7, 96-105.
- Yamamoto, M. et al. (2006) Nat Immunol 7, 962-70.
- Yamamoto, M. et al. (2006) J Immunol 177, 7520-4.
- Duncan, L.M. et al. (2006) EMBO J 25, 1635-45.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.